| Name | Title | Contact Details |
|---|
Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.
This is cannabis for real life. Cultivated by real people for real people. Shop online or find our products at dispensary near you.
Japan Telegraph and Telephone Public Corporation, a predecessor of NTT, started Data Communications business in 1967.
ClearVoice is a leading content marketing platform and freelancer marketplace. Complete with content discovery tools, the technology transparently connects brands, creators and publishers. Plan, recruit, create, distribute and measure in one place.
Kansas Archiving Service Internet is a Mcpherson, KS-based company in the Software and Internet sector.